Prediction of the mechanism of action of omuralide (clasto-lactacystin β-lactone) on human cathepsin A based on a structural model of the yeast proteasome β5/PRE2-subunit/omuralide complex

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1764, Issue 8, 2006, Pages 1372-1380

  Aikawa, Sei ichi ^a,c   Matsuzawa, Fumiko ^a,c   Satoh, Yurie ^b   Kadota, Yoshito ^b   Doi, Hirofumi ^a,c   Itoh, Kohji ^b,c  

^a Celestar Lexico Sciences Inc   (Japan)

^b Graduate School of Pharmaceutical Sciences   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cathepsin A; Chymostatin; Homology modeling; Lactacystin; Omuralide; Proteasome

Indexed keywords

AMINO ACID; CARBOXYPEPTIDASE C; GLYCINE; LACTACYSTIN BETA LACTONE; PROTEASOME; PROTEIN INHIBITOR; PROTEIN SUBUNIT; SERINE;

ARTICLE; BINDING SITE; CATALYSIS; CONFORMATION; CRYSTAL STRUCTURE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; X RAY ANALYSIS;

CARBOXYPEPTIDASE C; CATALYTIC DOMAIN; CYSTEINE ENDOPEPTIDASES; HUMANS; LACTONES; MACROMOLECULAR SUBSTANCES; MODELS, MOLECULAR; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

CATHA; TRITICUM AESTIVUM;

EID: 33747766494     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2006.05.008     Document Type: Article

References (32)

1. Jackman H.L., Tan F.L., Tamei H., Beurling-Harbury C., Li X.Y., Skidgel R.A., and Erdos E.G. A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal "protective protein". J. Biol. Chem. 265 (1990) 11265-11272
2. Itoh K., Takiyama N., Kase R., Kondoh K., Sano A., Oshima A., Sakuraba H., and Suzuki Y. Purification and characterization of human lysosomal protective protein expressed in stably transformed Chinese hamster ovary cells. J. Biol. Chem. 268 (1993) 1180-1186
3. Itoh K., Kase R., Shimmoto M., Satake A., Sakuraba H., and Suzuki Y. Protective protein as an endogenous endothelin degradation enzyme in human tissues. J. Biol. Chem. 270 (1995) 515-518
4. Galjart N.J., Gillemans N., Harris A., van der Horst G.T., Verheijen F.W., Galjaard H., and d'Azzo A. Expression of cDNA encoding the human "protective protein" associated with lysosomal beta-galactosidase and neuraminidase: homology to yeast proteases. Cell 54 (1988) 755-764
5. Rudenko G., Bonten E., d'Azzo A., and Hol W.G. Three-dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism. Structure 3 (1995) 1249-1259
6. d'Azzo A., Andria G., Strisciuglio P., and Galjaard H. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. (2000), McGraw-Hill, New York 3811-3826
7. Pshezhetsky A.V., Elsliger M.A., Vinogradova M.V., and Potier M. Human lysosomal beta-galactosidase-cathepsin A complex: definition of the beta-galactosidase-binding interface on cathepsin A. Biochemistry 34 (1995) 2431-2440
8. Hanna W.L., Turbov J.M., Jackman H.L., Tan F., and Froelich C.J. Dominant chymotrypsin-like esterase activity in human lymphocyte granules is mediated by the serine carboxypeptidase called cathepsin A-like protective protein. J. Immunol. 153 (1994) 4663-4672
9. Shimmoto M., Fukuhara Y., Itoh K., Oshima A., Sakuraba H., and Suzuki Y. Protective protein gene mutations in galactosialidosis. J. Clin. Invest. 91 (1993) 2393-2398
10. Leimig T., Mann L., Martin M.P., Bonten E., Persons D., Knowles J., Allay J.A., Cunningham J., Nienhuis A.W., Smeyne R., and d'Azzo A. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood 99 (2002) 3169-3178
11. Hahn C., Martin M., Zhou X., Mann L., and d'Azzo A. Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14880-14885
12. Korah N., Smith C.E., D'Azzo A., Mui J., and Hermo L. Characterization of cell- and region-specific abnormalities in the epididymis of cathepsin a deficient mice. Mol. Reprod. Dev. 66 (2003) 358-373
13. Itoh K., Oyanagi K., Takahashi H., Sato T., Hashizume Y., Shimmoto M., and Sakuraba H. Endothelin-1 in the brain of patients with galactosialidosis: its abnormal increase and distribution pattern. Ann. Neurol. 47 (2000) 122-126
14. Reminigton S.J., and Breddam K. Carboxypeptidases C and D. Methods Enzymol. 244 (1994) 231-248
15. Endrizzi J.A., Breddam K., and Remington S.J. 2.8-Å structure of yeast serine carboxypeptidase. Biochemistry 33 (1994) 11106-11120
16. Bullock T.L., Branchaud B., and Remington S.J. Structure of the complex of l-benzylsuccinate with wheat serine carboxypeptidase II at 2.0-Å resolution. Biochemistry 33 (1994) 11127-11134
17. Elsliger M.A., Pshezhetsky A.V., Vinogradova M.V., Svedas V.K., and Potier M. Comparative modeling of substrate binding in the S1′ subsite of serine carboxypeptidases from yeast, wheat, and human. Biochemistry 35 (1996) 14899-14909
18. Satoh Y., Kadota Y., Oheda Y., Kuwahara J., Aikawa S., Matsuzawa F., Doi H., Aoyagi T., Sakuraba H., and Itoh K. Microbial serine carboxypeptidase inhibitors: comparative analysis of actions on homologous enzymes derived from man, yeast and wheat. J. Antibiot. (Tokyo) 57 (2004) 316-325
19. Dick L.R., Cruikshank A.A., Destree A.T., Grenier L., McCormack T.A., Melandri F.D., Nunes S.L., Palombella V.I., Parent L.A., Plamondon L., and Stein R.L. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultures cells. J. Biol. Chem. 272 (1997) 182-188
20. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., and Schreiber S.L. Inhibition of preoteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268 (1995) 726-732
21. Ostrowska H., Wojcik C., Omura S., and Worowski K. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem. Biophys. Res. Commun. 234 (1997) 729-732
22. Ostrowska H., Wojcik C., Wilk S., Omura S., Kozlowski L., Stoklosa T., Worowski K., and Radziwon P. Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/beta-lactone is not a specific inhibitor of the proteasome. Int. J. Biochem. Cell Biol. 32 (2000) 747-757
23. The RCSB Protein Data Bank (http://www.pdb.org).
24. Bullock T.L., Breddam K., and Remington S.J. Peptide aldehyde complexes with wheat serine carboxypeptidase II: implications for the catalytic mechanism and substrate specificity. J. Mol. Biol. 255 (1996) 714-725
25. Groll M., Ditzel L., Lowe J., Stock D., Bochtler M., Bartunik H.D., and Huber R. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386 (1997) 463-471
26. Kabsch W. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A32 (1976) 922-923
27. Kabsch W. A discussion of the solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A34 (1978) 827-828
28. Omura S., Matsuzaki K., Fujimoto T., Kogure K., Furuya T., Fujita S., and Nakagawa S. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibiot. (Tokyo) 44 (1991) 117-118
29. Craiu A., Gaczynska M., Akopian T., Gramm C.F., Fenteany G., Goldberg A.L., and Rock H.L. Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272 (1997) 13437-13445
30. Figueiredo-Pereira M.E., Berg K.A., and Wilk S. A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem. 63 (1994) 1578-1581
31. Umezawa H. Structures and activities of protease inhibitors of microbial origin. Methods Enzymol. 45 (1976) 678-695
32. Shah I.M., Lees K.R., Pien C.P., and Elliot P.J. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 54 (2002) 269-276